120 -10 (84) 2025 - Khasanov A.B., Yusupov Sh.A. - IMMUNOHISTOCHEMICAL CHARACTERISTICS OF BONE TISSUE IN ALLOXAN OSTEOPATHY WITH EXPRESSION OF BONE REMODELING MARKERS

IMMUNOHISTOCHEMICAL CHARACTERISTICS OF BONE TISSUE IN ALLOXAN OSTEOPATHY WITH EXPRESSION OF BONE REMODELING MARKERS

Khasanov A.B. - Samarkand State Medical University

Yusupov Sh.A. - Samarkand State Medical University

Resume

The aim of the study was to examine the immunohistochemical and morphofunctional characteristics of bone tissue in alloxan osteopathy and evaluate the effectiveness of correction using calcium gluconate and sulfated glycosaminoglycans. The experiment was conducted on 48 rats divided into four groups: control, alloxan-induced diabetes without treatment, calcium gluconate therapy, and combination therapy with calcium gluconate and glycosaminoglycans. Bone morphometry, the expression of collagen I, osteocalcin, osteoprotegerin (OPG), and RANK receptor ligand (RANKL), as well as serum biochemical parameters and bone mineral density (BMD), were studied. Alloxan-induced diabetes was accompanied by significant morphological changes, including decreased trabecular thickness, osteoid area, and osteoblast count, decreased expression of collagen I, osteocalcin, and OPG, and increased RANKL levels. Decreased calcium and phosphorus concentrations, increased alkaline phosphatase activity, and hyperglycemia were observed, as well as a significant decrease in femur and vertebral BMD. Combination therapy with calcium gluconate and sulfated glycosaminoglycans helped normalize biochemical parameters, restore bone structure, and increase bone mineral density. The combined use of calcium and sulfated glycosaminoglycans has a pronounced osteoprotective effect in alloxan osteopathy, restoring the balance of bone remodeling and improving the structural and functional state of bone tissue. The obtained data confirm the potential of this combination for the prevention and correction of diabetes-associated osteopenic conditions.

Keywords: alloxan osteopathy, collagen I, osteocalcin, osteoprotegerin, RANKL, calcium, sulfated glycosaminoglycans, bone mineral density.

First page

687

Last page

694

For citation:Khasanov A.B., Yusupov Sh.A. - IMMUNOHISTOCHEMICAL CHARACTERISTICS OF BONE TISSUE IN ALLOXAN OSTEOPATHY WITH EXPRESSION OF BONE REMODELING MARKERS//New Day in Medicine 10(84)2025 687-694 https://newdayworldmedicine.com/en/new_day_medicine/10-84-2025

List of References

1. Арутюнян А.В., Неробкова Л.Н., Петрова В.И. Морфофункциональные изменения костной ткани при сахарном диабете. // Морфология. 2020;157(4):45-52.
2. Бережная Н.М., Коваленко В.Н. Остеокальцин как маркер костного метаболизма. // Патологическая физиология и экспериментальная терапия. 2019;2:67-73.
3. Зорина А.В., Корнилов Н.В. Молекулярные механизмы ремоделирования костной ткани: роль системы OPG/RANK/RANKL. // Успехи современной биологии. 2021;141(3):224-232.
4. Семенова И.В., Павлов П.А. Иммуногистохимические методы в исследовании костной ткани. // Архив патологии. 2020;82(5):38-44.
5. Кравченко Е.А., Беляева О.Н. Диабетическая остеопатия: современные представления о патогенезе и лечении. // Эндокринология. 2022;68(2):115-123.
6. Pramojanee S.N., Phimphilai M., Chattipakorn N., Chattipakorn S.C. Possible roles of insulin signaling in osteoblasts. // Endocrine Research. 2019;44(1):73-84.
7. Mohsin S., Baniyas M.M., et al. Osteoporosis and diabetes – a review. // Frontiers in Endocrinology. 2019;10:355.
8. Fan Y., Hanai J.I., Le P.T., Bi R., Maridas D. et al. Parathyroid hormone directs bone formation via interacting with bone marrow adipocytes. // Journal of Clinical Investigation. 2017;127(8):3041-3054.
9. Khosla S., Hofbauer L.C. Osteoporosis treatment: recent developments and ongoing challenges. // Lancet Diabetes Endocrinol. 2017;5(11):898-907.
10. Zhao B. The role of RANKL and OPG in bone metabolism. // Molecular Medicine Reports. 2021;23(5):363-370.

    file

    download